These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Echigoya Y; Yokota T Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394 [TBL] [Abstract][Full Text] [Related]
4. In Vivo Evaluation of Dystrophin Exon Skipping in mdx Mice. Wu B; Wang M; Shah S; Lu QL Methods Mol Biol; 2018; 1828():231-247. PubMed ID: 30171545 [TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089 [TBL] [Abstract][Full Text] [Related]
6. Use of Small Animal Models for Duchenne and Parameters to Assess Efficiency upon Antisense Treatment. Lu-Nguyen N; Malerba A; Popplewell L Methods Mol Biol; 2022; 2434():301-313. PubMed ID: 35213026 [TBL] [Abstract][Full Text] [Related]
7. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. Kemaladewi DU; Hoogaars WM; van Heiningen SH; Terlouw S; de Gorter DJ; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; ten Dijke P; 't Hoen PA BMC Med Genomics; 2011 Apr; 4():36. PubMed ID: 21507246 [TBL] [Abstract][Full Text] [Related]
8. Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice. Lu-Nguyen NB; Jarmin SA; Saleh AF; Popplewell L; Gait MJ; Dickson G Mol Ther; 2015 Aug; 23(8):1341-1348. PubMed ID: 25959011 [TBL] [Abstract][Full Text] [Related]
9. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
10. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737 [TBL] [Abstract][Full Text] [Related]
11. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. Hanson B; Wood MJA; Roberts TC RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516 [TBL] [Abstract][Full Text] [Related]
12. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice. Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548 [TBL] [Abstract][Full Text] [Related]
13. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting. Maruyama R; Yokota T Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217 [TBL] [Abstract][Full Text] [Related]
14. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Yin H; Betts C; Saleh AF; Ivanova GD; Lee H; Seow Y; Kim D; Gait MJ; Wood MJ Mol Ther; 2010 Apr; 18(4):819-27. PubMed ID: 20068555 [TBL] [Abstract][Full Text] [Related]
15. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]